Thank You!

Thank You!

We will keep you updated

In the meantime, follow us on our social media and see other Median contents that may interest you

  • The latest from Median

    Median Technologies has been selected as a preferred clinical trial imaging services provider for another leading global pharmaceutical company.
    Median will be exhibiting at the 2024 ASCO Annual Meeting, which will take place from May 31 to June 4 in Chicago, IL.  Meet us  to learn more about our breakthrough imaging solutions and services for oncology clinical trials.
    Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”) today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited) for the first quarter of 2024, as of March 31, 2024.
    Median Technologies (ALMDT) unveils a new identity, including a new name, logo, tagline for its iBiopsy® AI/ML tech-based suite of software as medical devices (SaMD) and business unit, as part of an extensive rebranding initiative.